Gilead Sciences: Hepatitis-C Prescriptions Fall, So Does the Stock

RBC’s Michael Yee has the latest prescription data for Gilead Sciences (GILD) hepatitis-C treatments: Sipa USA/Associated Press Harvoni Total Rx 9646 (-4% wk/wk), New Rx 3619 (-6% wk/wk); Harvoni+Sovaldi TRx 11466 (-4% wk/wk), NRx 4231 (-5% wk/wk) (ending 4/17/15). Gileads’s weekly Hep C scripts are tracking towards $12.5B USA (above cons ~ $10.2-12B USA, $14.6B [...]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.